Al-Sharraf, M., Metch, B., Krish, J., Ensley, J., Rinehart, J., Schuller, D., Coltman, C. (1987) Platinum analogues in recurrent and advanced head and neck cancer. Cancer Treatment Reports 71 (7–8): 723–726.
Anzai, T., Asukimas, S., Snow, J. (1987) Ototoxicity of carboplatin and its transferability into inner ear-comparative study of carboplatin. Ear Research Japan 18: 122–124
Calvert, A., Harland, S., Newell, D., Siddik, Z., Jones, A., McElivan, J., Raju, S., Whiltshaw, E., Smith, D., Baker, J., Peckham, M., Harrop, K. (1982) Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemotherapy and Pharmacology 9: 140–147
Castello, M., Clerico, A., Deb, G., Dominici, C, Fidani, P., Donfrancesco, A. (1990) High dose carboplatin in combination with etoposide for childhood brain tumours. American Journal of Pediatric Hematology/Oncology 12(3): 297–300.
Evans, W. K., Eisenhower, E., Hughes, P., Maroun, J., Ayoub, J., Shepard, E., Feld, R. (1988) VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer. British Journal of Cancer 58 (4): 464–468
Kennedy, I., Fitzharris, B., Colls, B., Atkinson, C. (1990) Carboplatin is ototoxic. Cancer Chemotherapy and Pharmacology 26 (3): 232–234
Komune, S., Asukimas, S., Snow, J. (1981) Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum in the male rat. Cancer Chemotherapy Reports 55: 1–8
Leyvraz, S., Ohnuma, X., Lassus, M., Holland, J. (1985) Phase I study of carboplatin in patients with advanced cancer, intermittent intravenous bolus and 24 hour infusion. Journal of Clinical Oncology 3 (10), 1385–1392.
Myers, E., Welborn, J., Lewis, J., Flynn, N. (1989) Infusion carboplatin treatment for relapsed and refractory acute leukaemia. Journal of Clinical Oncology 7 (2): 173–178
Nichols, C, Truot, G., Williams, S., van Besien, K., Laehrer, P., Roth, B., Akard, L., Hoffman, R., Goulet, R., Wolff, S. (1989) Dose intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplant. Journal of Clinical Oncology 7(7): 932–939.
Rosenberg, B., van Camp, L., Krigas, T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699
Rosenberg, B., van Camp, L., Trosko, J., Mansow, J. (1969) Platinum compounds: a new class of potent antitumour agents. Nature 111: 385–386
Saito, T, Saito, H., Saito, K., Wakui, S., Manabe, Y., Tsuda, G. (1989) Ototoxicity of carboplatin in guinea pigs. Auris-Nasus-Larynx 16 (1): 13–21
Schweitzer, V., Rarey, K., Dolon, D., Abrams, G., Litterst, C., Sheridan, C. (1986) Ototoxicity of cisplatin versus platinum analogues CBDCA (JM-8) and CHIP (JM-9). Otolaryngology—Head and Neck Surgery 94 (4): 458–470
Stadnick, S., Fleischman, R., Scheppi, U., Merrian, P. (1975) Cisdichlorodiammineplatinum II - hearing loss and other toxic effects in rhesus monkeys. Cancer Chemotherapy Reports 59: 467–480
Van der Hulst, R., Dreschler, W., Urbanus, N. (1988) High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Annals of Otology, Rhinology and Laryngology 97: 133–137
Van Hennik, M., van der Vijgh, W., Klein, I., Elferink, E., Vermorken, J., Winograd, B., Pinedo, H. (1987) Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Research 47: 6297–6301
Woloschuk, D., Pruemer, J., Cluxton, R. (1988) Carboplatin: a new cisplatin analog. Drug Intelligence and Clinical Pharmacy 22: 843–849
Wright, C, Shaeffer, S. (1982) Inner ear histopathology in patients treated with cisplatin. Laryngoscope 92: 1408–1413
